Navigation Links
LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available
Date:11/16/2009

WOODCLIFF LAKE, N.J., Nov. 16 /PRNewswire/ -- Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. The U.S. Food and Drug Administration (FDA) approved LUSEDRA in December 2008. LUSEDRA is designated as a Schedule IV drug.

"We are pleased to offer the anesthesiology community a new option for their patients undergoing sedation," said Randi Fain, MD, FCCP, Director, Medical Affairs, Oncology and Institutional Care, Eisai Inc. "LUSEDRA will play an important role in the Eisai institutional care portfolio."

Eisai is committed to fulfilling unmet medical needs for patients as part of its human health care mission.

About LUSEDRA(TM) (fospropofol disodium) Injection

LUSEDRA(TM) (fospropofol disodium) Injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by alkaline phosphatase enzymes in the body into propofol. There are two dosing regimens for LUSEDRA: standard or modified. Standard dosing regimen is for patients 18 to <65 years of age who are healthy or have mild systemic disease. The modified dosing regimen is for patients who are 65 years of age or older or have severe systemic disease.

Important Safety Information

LUSEDRA should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the diagnostic or therapeutic procedure. Patients should be continuously monitored during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. Facilities for providing car
'/>"/>

SOURCE Eisai Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
2. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
3. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
7. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
8. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
9. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Boston Scientific Corporation (NYSE: BSX ... Scientific Program May 21-24 in Paris ... particularly rich and diversified set of data this year ... M.D., global chief medical officer, Boston Scientific.  "The primary ... the NG PROMUS trial, which evaluated our Promus PREMIER ...
(Date:5/16/2013)... and MECHELEN, Belgium , May 17, ... (NYSE: ABBV ) announced today an extension ... disease.  Galapagos will fund and complete a Phase 2 ... rapid progression into Phase 3.  Upon successful completion of ... Galapagos $50 million.  The terms of the collaboration extension ...
(Date:5/16/2013)... -- Nektar Therapeutics, (Nasdaq: NKTR ) President and Chief ... scheduled to present at the upcoming 2013 UBS Global Healthcare ... Sheraton New York Hotel on Tuesday, May 21, 2013 at ... accessible via a Webcast through a link posted in the ... http://www.nektar.com . This Webcast will be available for replay until ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... INTERIM DATA FROM PHASE 3 CLINICAL TRIAL FOR NATURLOSE(R) ... (Nasdaq: SPEX ), an innovator in biotechnology ... to food, supplement, biotechnology and pharmaceutical companies, today announced ... Previously scheduled for May, the meeting will instead be ...
... CSL Behring has been informed by the U.S. Food ... first FDA-approved treatment of acute bleeding episodes in patients ... seven years of orphan-drug exclusivity. RiaSTAP was approved ... the treatment of acute bleeding episodes in patients with ...
Cached Medicine Technology:Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data 2Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data 3CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 2CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 3CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 4
(Date:5/18/2013)... Simple changes in a person’s every day ... more water can lead to substantial health benefits, the ... overall. Diet Doc understands that overcoming significant ... be difficult and often requires the use of prescription ... patients get over initial weight loss hurdles. In addition ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... The American Society for Dermatologic Surgery ... (D) to sign a bill (HB 2896) that would ... age of 18 from tanning indoors. , With Gov. ... the nation to enact an under-18 tanning ban. California ... for minors. Nationwide, 34 states and the District of ...
(Date:5/18/2013)... Scott Tischler of Tischler Brothers Fitness helped ... keys to losing weight played a huge part in Troy ... Tischler, Troy was able to lose a pound a day. ... should be approached with caution and any activity should be ... keys to weight loss that Scott Tischler advocates. With these ...
(Date:5/18/2013)... New York, NY (PRWEB) May 18, 2013 ... now available at Condomania, America’s favorite condom store recently ... sampler packs to the store's large selection of condoms ... condoms sampler packs make it easy to try different ... on the market. Featuring Kimono’s classic comfortable shape ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Kimono Condoms Assorted Sampler Packs Now Available at Condomania 2
... The cold and flu season is upon us again. This year ... flu and some will even die from it. The latest victim ... small firm in Phoenix, Arizona comes to the rescue. This firm, ... cold and flu products. Unlike all of the competing cold and ...
... have countless conversations with ourselves, and if we really listen ... to ourselves is critical, judgmental, and often unforgiving. We seem ... tend to make excuses and blame others, or we blame ... shortcomings. Carol Messmer,s new book, "Conversations with ...
... Care Guidelines will be used to Combat Waste in ... permanent Recovery Audit Contractor (RAC) for the Centers for ... license agreement with Milliman Care Guidelines (R). ... and software to review Medicare claims. HDI is the ...
... March 3 /PRNewswire-FirstCall/ -- The Providence ... announced that Avalon Correctional Services (Pink Sheets: CITY) ... against Providence. "We are delighted that Avalon and ... recognized that continuing their consent solicitation is not ...
... Minnesota Dance and Exercise Entrepreneur Releases 15 Original ... 3 Dancercise Kids(R), a provider of unique ... announced that its founder, Tessa Pfeifer, has released ... on bringing Dancercise(R) concepts into every home.Packed with ...
... a Grant from Otsuka America Pharmaceutical, Inc.ROCKVILLE, Md., March ... three universities as the recipients of Helping Hands Grants. ... to $5,000 for a community mental health service project ... of medical faculty. The awards are made possible ...
Cached Medicine News:Health News:Discovery Yields Cure for the Common Cold and the Flu 2Health News:'Conversations with Self: Discovering the Power of Your Inner Voice': Discover How to Find and Listen to an Inner Voice That Is Encouraging and Helpful 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 3Health News:Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation 2Health News:Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation 3Health News:Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation 4Health News:New Kids' CD Encourages Kids to Get Active and Stay Healthy 2Health News:American Psychiatric Foundation Announces Recipients of Helping Hands Grants 2Health News:American Psychiatric Foundation Announces Recipients of Helping Hands Grants 3
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Sabre 180 is a powerful niche generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: